Skip to main content

Nasdaq News

Cash Dividend On The Way From Bel Fuse (BELFA)

2 days 8 hours ago
Looking at the universe of stocks we cover at Dividend Channel, on 10/15/26, Bel Fuse Inc (Symbol: BELFA) will trade ex-dividend, for its quarterly dividend of $0.06, payable on 10/30/26. As a percentage of BELFA's recent stock price of $184.66, this dividend works out to appro
BNK Invest

Barclays initiates coverage of AZZ at Equal-Weight

2 days 8 hours ago
Fintel reports that on October 14, 2026, Barclays initiated coverage of AZZ (NYSE:AZZ) (DB:AI7) with a Equal-Weight recommendation.Prior to this coverage initiation, the stock closed at $136.71 on October 13, 2026. This latest close of $136.71 represents a one-week price change o
Fintel

Dow Movers: NVDA, HONIV

2 days 8 hours ago
In early trading on Wednesday, shares of Honeywell International topped the list of the day's best performing Dow Jones Industrial Average components, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain. And the worst performing Dow component thus far
BNK Invest

NAD Ex-Dividend Reminder - 10/15/26

2 days 8 hours ago
Looking at the universe of stocks we cover at Dividend Channel, on 10/15/26, Nuveen Dividend Advantage Municipal Fund (Symbol: NAD) will trade ex-dividend, for its monthly dividend of $0.0705, payable on 11/2/26. As a percentage of NAD's recent stock price of $10.15, this divid
BNK Invest

Stocks Finish Lower Ahead of Wednesday’s CPI Report

2 days 8 hours ago
The S&P 500 Index ($SPX ) (SPY ) closed down by -0.02% on Tuesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.31%. December E-mini S&P futures (ESZ26 ) fell -0.02%, and December E-mini...
Barchart

Takeda's TAK-881 Cuts Infusion Time By 42.6% In Phase 3 PID Study

2 days 8 hours ago
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK), a biopharmaceutical company developing treatments for rare diseases and other conditions, presented detailed Phase 2/3 IgGNITE study results for its investigational subcutaneous therapy TAK-881 in patients with Primary Immu
RTTNews
Checked
6 minutes 55 seconds ago
This feed is responsible for generating the rss feed related to the topic latest article
Subscribe to Nasdaq News feed